Contact this trialFirst, we need to learn more about you.
Anti-metabolites
Capecitabine + Neratinib for Breast Cancer
Recruiting1 awardPhase 1 & 2
Commack, New York
This trial is testing the safety of combining two drugs, neratinib and capecitabine, in a new dosing schedule for patients with advanced breast cancer. The goal is to find out if this new schedule is safer and more effective. Neratinib blocks proteins that help cancer grow, and capecitabine stops cancer cells from multiplying.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service